Assuntos
Quinase do Linfoma Anaplásico/genética , Carcinoma Pulmonar de Células não Pequenas/genética , Neoplasias Pulmonares/genética , Tromboembolia/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma Pulmonar de Células não Pequenas/patologia , Feminino , Rearranjo Gênico , Humanos , Incidência , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Portugal/epidemiologia , Prognóstico , Receptores Proteína Tirosina Quinases/genética , Estudos Retrospectivos , Espanha/epidemiologia , Análise de Sobrevida , Tromboembolia/genética , Adulto JovemRESUMO
BACKGROUND: Apixaban and rivaroxaban are two direct-acting oral anticoagulants (DOACs) recommended for thromboprophylaxis in cancer patients treated with chemotherapy in an ambulatory setting. We aimed to assess the cost-utility of thromboprophylaxis with apixaban and rivaroxaban vs no thromboprophylaxis in ambulatory cancer patients starting chemotherapy with an intermediate-to-high risk of venous thromboembolism (VTE), Khorana score ≥ 2 points. METHODS: A cost-effectiveness analysis was performed from the perspective of Spain's National Health System (NHS) using an analytical decision model in the short-term (180 days) and a Markov model in the long-term (5 years). Transition probabilities were obtained from randomized, double-blind, placebo-controlled clinical trials of apixaban and rivaroxaban in adult ambulatory patients with cancer at risk for VTE, treated with chemotherapy (AVERT and CASSINI trials). The costs (2,021) were taken from Spanish sources. The utilities of the model were obtained through the EQ-5D questionnaire. Deterministic (base case) and probabilistic (second-order Monte Carlo simulation) analyses were conducted. RESULTS: In the probabilistic sensitivity analysis, apixaban generated a cost per patient of 1,082 ± 187, with a 95% confidence interval (CI) of 713-1,442, while no prophylaxis produced a cost per patient of 1,146 ± 218, with a 95% CI of 700-1,491, with a saving of 64 per patient and a gain of 0.008 QALYs. Likewise, rivaroxaban provided a cost per patient of 993 ± 133, with a 95% CI of 748-1,310, while no prophylaxis produced a cost per patient of 872 ± 152, with a 95% CI of 602-1,250, with an additional expense of 121 per patient and a gain of 0.008 QALYs. CONCLUSIONS: In thromboprophylaxis of cancer patients, the use of apixaban and rivaroxaban generated similar costs compared to non-prophylaxis, without the difference found being statistically significant, with a clinically insignificant QALY gain.
Assuntos
Neoplasias , Tromboembolia Venosa , Adulto , Humanos , Anticoagulantes , Análise Custo-Benefício , Neoplasias/complicações , Neoplasias/tratamento farmacológico , Piridonas/uso terapêutico , Rivaroxabana/uso terapêutico , Espanha , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
INTRODUCTION: Patients with cancer and venous thromboembolism (VTE) show a high risk of VTE recurrence during anticoagulant treatment. This study aimed to develop a predictive model to assess the risk of VTE recurrence within 6 months at the moment of primary VTE diagnosis in these patients. MATERIALS AND METHODS: Using the EHRead® technology, based on Natural Language Processing (NLP) and machine learning (ML), the unstructured data in electronic health records from 9 Spanish hospitals between 2014 and 2018 were extracted. Both clinically- and ML-driven feature selection were performed to identify predictors for VTE recurrence. Logistic regression (LR), decision tree (DT), and random forest (RF) algorithms were used to train different prediction models, which were subsequently validated in a hold-out data set. RESULTS: A total of 16,407 anticoagulated cancer patients with diagnosis of VTE were identified (54.4 % male and median age 70). Deep vein thrombosis, pulmonary embolism and metastases were observed in 67.2 %, 26.6 %, and 47.7 % of the patients, respectively. During the study follow-up, 11.4 % of the patients developed a recurrent VTE, being more frequent in patients with lung cancer. Feature selection and model training based on ML identified primary pulmonary embolism, deep vein thrombosis, metastasis, adenocarcinoma, hemoglobin and serum creatinine levels, platelet and leukocyte count, family history of VTE, and patients' age as predictors of VTE recurrence within 6 months of VTE diagnosis. The LR model had an AUC-ROC (95 % CI) of 0.66 (0.61, 0.70), the DT of 0.69 (0.65, 0.72) and the RF of 0.68 (0.63, 0.72). CONCLUSIONS: This is the first ML-based predictive model designed to predict 6-months VTE recurrence in patients with cancer. These results hold great potential to assist clinicians to identify the high-risk patients and improve their clinical management.
Assuntos
Embolia Pulmonar , Tromboembolia Venosa , Trombose Venosa , Humanos , Idoso , Lactente , Tromboembolia Venosa/tratamento farmacológico , Tromboembolia Venosa/etiologia , Recidiva Local de Neoplasia/induzido quimicamente , Recidiva Local de Neoplasia/tratamento farmacológico , Anticoagulantes/uso terapêutico , Embolia Pulmonar/tratamento farmacológico , Trombose Venosa/tratamento farmacológico , Aprendizado de Máquina , Recidiva , Fatores de RiscoRESUMO
INTRODUCTION: We aimed to determine if advanced BRAF-mutant NSCLC has a higher thromboembolic events (TEE) rate than the expected. METHODS: Between 2008 and 2021, 182 patients with BRAF-mutant advanced NSCLC (BRAF V600E, n = 70; BRAF non-V600E, n = 112) were retrospectively identified from 18 centers in Spain. Patients received chemotherapy (n = 147), immunotherapy (n = 69), targeted therapy (n = 42), and immunotherapy + chemotherapy (n = 26). RESULTS: Incidence rate of TEE was 26.4 % (95%CI: 19.9 %-32.9 %). A total of 72 TEE were documented among 48 patients, as 18 patients (37.5 %) developed more than one event. Median time to TEE onset was 2 months, 69 % of TEE occurred in the peridiagnostic period (+/- 90 days from cancer diagnosis), and in 16 pts. (33 %) TEE was the form of lung cancer presentation. Although most TEE were only venous (82 %; PE, n = 33; DVT, n = 16), arterial events were reported in 31 % and occurred earlier, or TEE presented in atypical locations (13.9 %). TEE were related to high hospitalization rate (59 %), recurrence (23 %), and mortality (10.4 %) despite appropriate anticoagulant/antiaggregant treatment. Median OS in patients without-TEE was 19.4 months (95%CI: 4.6-34.1), and significantly shorter in patients with arterial-TEE vs venous-TEE vs both of them: 9.9 months (95%CI: 0-23.5) vs 41.7 months (95%CI: 11.3-72.2 m) vs 2.7 months (95%CI: 2.1-3.3), p = 0.001. Neither clinical or molecular features (BRAF V600E/non-V600E), nor cancer treatment was associated to TEE occurrence. Khorana score underperformed to predict thrombosis at cancer diagnosis, as only 19.2 % of patients were classified as high-risk. CONCLUSIONS: Thrombotic events represent a new clinical feature of BRAF-mutant lung cancer. Patients with almost a 30 % incidence of TEE should be offered systematic anticoagulation.
Assuntos
Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares , Tromboembolia , Humanos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Incidência , Neoplasias Pulmonares/epidemiologia , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/tratamento farmacológico , Mutação , Proteínas Proto-Oncogênicas B-raf/genética , Estudos Retrospectivos , Tromboembolia/etiologia , Tromboembolia/genéticaRESUMO
Cancer patients exhibit an increased risk of venous thromboembolism (VTE), with VTE being the second leading cause of morbidity and mortality in these patients. The implementation of lockdowns following the COVID-19 pandemic has resulted in decreased mobility and delayed access to care, thus further increasing the susceptibility to VTE. Cancer patients may also be at a higher risk of SARS-CoV-2 infection and have been shown to be more likely to experience severe COVID-19 disease compared to patients without cancer. Given that both cancer and COVID-19 exhibit a hypercoagulable state, stasis of blood flow, and endothelial injury, cancer patients with COVID-19 constitute a vulnerable population with a high risk of thrombosis and bleeding. However, to date there are limited studies evaluating whether cancer patients infected with SARS-CoV-2 have a higher VTE incidence than COVID-19 patients without cancer, how to assess the risk of VTE, prophylaxis and treatment in this special population. Herein, we highlight the urgent need for studies in cancer patients with COVID-19 to ensure appropriate patient care and improve clinical outcomes.
RESUMO
PURPOSE: Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy and overall prognosis remains poor, with a median survival of less than 24 months. Sequencing studies have revealed a high prevalence of genomic alterations in CCA, with multiple potential therapeutic targets. Next-generation sequencing (NGS) can identify actionable mutations such as FGFR, IDH, BRAF, ERBB2, ROS1, or microsatellite instability (MSI-H), among others. METHODS: We conducted a retrospective multicenter study in Spain in 2019. Thirty consecutive patients from 15 centers were included. All patients were diagnosed with advanced CCA and underwent NGS (FoundationOne®) in 2019. Twenty-four patients underwent tissue-based NGS (FoundationOne® CDx), and 6 patients underwent blood-based NGS (FoundationOne®Liquid) with sequencing panels of 324 and 70 genes, respectively RESULTS: We identified 12 patients (40%) with an actionable genetic alteration in tissue: 2 FGFR2 fusions, 6 IDH1 mutations, 1 ERBB2 mutation, 1 ROS1 fusion, 1 PIK3CA mutation, and 1 MSI-H. CONCLUSION: Comprehensive genomic profiling (CGP) in cholangiocarcinoma can identify, in a high proportion of patients, clinically relevant genomic alterations that can lead to targeted therapies, expanding treatment options.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias dos Ductos Biliares/tratamento farmacológico , Biomarcadores Tumorais/genética , Colangiocarcinoma/tratamento farmacológico , Medicina de Precisão/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/farmacologia , Neoplasias dos Ductos Biliares/diagnóstico , Neoplasias dos Ductos Biliares/genética , Ductos Biliares/patologia , Biomarcadores Tumorais/antagonistas & inibidores , Colangiocarcinoma/diagnóstico , Colangiocarcinoma/genética , Análise Mutacional de DNA , Feminino , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Instabilidade de Microssatélites , Pessoa de Meia-Idade , Terapia de Alvo Molecular/métodos , Mutação , Prognóstico , Estudos Retrospectivos , EspanhaRESUMO
BACKGROUND: Optimal risk stratification of unsuspected pulmonary embolism (UPE) in ambulatory cancer patients (ACPs) remains unclear. Existing clinical predictive rules (CPRs) are derived from retrospective databases and have limitations. The UPE registry is a prospective international registry with pre-specified characteristics of ACPs with a recent UPE. The aim of this study was to assess the utility of risk factors captured in the UPE registry in predicting proximate (30-, 90- and 180-day) mortality and how they performed when applied to an existing CPR. OBJECTIVES: To evaluate risk factors for proximate mortality, overall survival, recurrent venous thromboembolism and major bleeding, in the patients enrolled in the UPE registry cohort. METHODS: Data from the 695 ACPs in this registry were subjected to multivariate logistic regression analyses to identify predictors independently associated with proximate mortality and overall survival. The most consistent predictors were applied to the Hull CPR, an existing 5-point prediction rule. RESULTS: The most consistent predictors of mortality were patient-reported respiratory symptoms within 14 days before, and ECOG performance status at the time of UPE. These predictors applied to the Hull-CPR produced a consistent correlation with proximate mortality and overall survival (area under the curve [AUC] = 0.70 [95% CI 0.63, 077], AUC = 0.65 [95% CI 0.60, 070], AUC = 0.64 [95% CI 0.59, 068], and AUC = 0.61, 95% CI 0.57, 0.65, respectively). CONCLUSION: In ACPs with UPE, ECOG performance status logged contemporaneously to the UPE diagnosis and respiratory symptoms prior to UPE diagnosis can stratify mortality risk. When applied to the HULL-CPR these risk predictors confirmed the risk stratification clusters of low-intermediate and high-risk for proximate mortality as seen in the original derivation cohort.
Assuntos
Neoplasias , Embolia Pulmonar , Estudos de Coortes , Humanos , Neoplasias/complicações , Neoplasias/diagnóstico , Prognóstico , Estudos Prospectivos , Embolia Pulmonar/diagnóstico , Estudos Retrospectivos , Medição de Risco , Fatores de RiscoRESUMO
INTRODUCTION: Based on the high incidence of thromboembolic events (TEs) observed in lung adenocarcinomas with ALK translocations and taking into account the biological proximity of ROS1 and ALK, we conducted a retrospective analysis of patients with advanced lung carcinoma carrying rearrangements in ROS1 from 23 centres in Spain and one centre in Portugal. METHODS: The main objective of the study was to analyse the incidence of TE in this population, looking for predictive risk factors, and its impact on overall survival. RESULTS: A total of 58 patients were included. The incidence of TEs throughout the disease was 46.6% (n = 27) with a median follow-up of 19 months (range: 1-78 months) and a median overall survival of 52 months in the total population and 50 months for the patients presenting TEs, with a hazards ratio of 1.12 (95% confidence interval: 0.47-2.65) p = 0.78. The majority of the events were venous (n = 24; 89%) and occurred in the ambulatory setting (n = 18; 67%). Almost half of the patients (n = 13; 48%) presented the TE in the peri-diagnostic period. CONCLUSIONS: The high incidence of thrombosis, especially during the cancer diagnosis process, requires special attention from a clinician. Despite the limitations of such a small descriptive study, its results are in accordance with previously reported data. It would be important to design prospective studies of antithrombotic prophylaxis in this population because of their possible impact in reducing the risk of TEs.
Assuntos
Carcinoma Pulmonar de Células não Pequenas/genética , Neoplasias Pulmonares/genética , Proteínas Tirosina Quinases/genética , Proteínas Proto-Oncogênicas/genética , Tromboembolia/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Pulmonar de Células não Pequenas/complicações , Feminino , Rearranjo Gênico , Humanos , Incidência , Neoplasias Pulmonares/complicações , Masculino , Pessoa de Meia-Idade , Tromboembolia/epidemiologiaRESUMO
The association between cancer and thrombosis is well established. Venous thromboembolism (VTE) is considered a main cause of mortality and morbidity in cancer patients and is commonly underestimated by oncologists. In recent years the incidence rates of VTE have notably increased. Several studies have clearly shown that cancer patients who are diagnosed with VTE present a poorer prognosis. The Spanish Society of Medical Oncology (SEOM) presents the guidelines for thrombosis and cancer in order to improve the prevention and management of VTE.
Assuntos
Oncologia/métodos , Neoplasias/terapia , Trombose/terapia , Anticoagulantes/uso terapêutico , Cateterismo Venoso Central , Humanos , Neoplasias/complicações , Recidiva , Fatores de Risco , Sociedades Médicas , Trombose/complicações , Trombose/diagnóstico , Fatores de Tempo , Resultado do TratamentoRESUMO
African Americans (AAs) tend to have lower total adiponectin levels compared to European Americans (EA); however, it is not known whether race affects adiponectin multimer distribution and their relationships to metabolic traits. We measured total adiponectin, high molecular weight (HMW), low molecular weight (LMW) (i.e., hexamer), and trimer adiponectin in 132 normoglycemic premenopausal women (75 AAs, 57 EAs), together with measures of total and abdominal fat, plasma lipids, insulin sensitivity (S(i)), and genetic admixture estimates. We found that lower total adiponectin in AAs was explained by reduced LMW, and trimer forms because levels of HMW did not differ between races. In EAs, HMW was highly correlated with multiple metabolic syndrome traits. In contrast, the LMW and trimer forms were most highly correlated with metabolic traits in AAs, including abdominal adiposity, lipids, and S(i). At similar levels of visceral adiposity, AAs exhibited significantly lower LMW adiponectin than EAs. Similarly, at comparable levels of HMW and LMW adiponectin, AAs were more insulin resistant than their EA counterparts. In conclusion, (i) serum adiponectin is lower in AAs predominantly as a result of reduced concentrations of LMW and trimers multimeric forms; (ii) LMW and trimer, not HMW, are most broadly correlated with metabolic traits in AAs. Thus, HMW adiponectin may exert less bioactivity in explaining the metabolic syndrome trait cluster in populations of predominant African genetic background.
Assuntos
Adiponectina/sangue , Negro ou Afro-Americano , Gordura Intra-Abdominal , População Branca , Adulto , Composição Corporal , Índice de Massa Corporal , Colesterol/sangue , Feminino , Humanos , Resistência à Insulina/etnologia , Peso Molecular , Pré-Menopausa , Triglicerídeos/sangueRESUMO
La hipertrofia ventricular izquierda (HVI) tiene valor pronóstico en los pacientes con hipertensión arterial (HTA); se requiere de un método de detección económico y fiable. Objetivo: establecer la utilidad de los criterios electrocardiográficos de voltaje para el diagnóstico de HVI en pacientes con HTA y análisis de los criterios una vez estratificada la HVI. Se realiza un estudio prospectivo de 255 pacientes consecutivos con HTA (161 mujeres, 94 hombres, edad media 59,6 ñ 14 años) con ECG basal y ecocardiograma M y 2-D, en forma independiente y ciega. Se estudia la sensibilidad (S), especificidad (E) y exactitud (EX) diagnóstica de 12 criterios electrocardiográficos de HVI, definida por grosor parietal y masa ventricular con el ecocardiograma. La sensibilidad de todos los criterios es baja (0.05-0.20), con especificidad más elevada (0.87-1), con exactitud varía entre 0.31-0.47. Al estratificar la HVI en leve, moderada y severa, la sensibilidad y especificidad de los criterios electrocardiográficos no cambian, incrementándose la exactitud. Sugerimos un nuevo índice: (RV6-RV5)2+(SV3-SV1)2 mayor 10 mm en 125/165 con HVI y 56/90 sin HVI (S = 0.76, E= 0.62 y EX = 0.38). Conclusiones: los criterios electrocardiográficos de voltaje para diagnóstico de HVI en pacientes con HTA tiene baja sensibilidad con alta especificidad. La exactitud es mayor cuanto mayor es el grado de HVI, sin modificar la sensibilidad(AU)
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Hipertrofia Ventricular Esquerda/diagnóstico , Hipertrofia Ventricular Esquerda/fisiopatologia , Hipertensão/complicações , Eletrocardiografia , Hipertrofia Ventricular Esquerda/etiologia , Sensibilidade e EspecificidadeRESUMO
La hipertrofia ventricular izquierda (HVI) tiene valor pronóstico en los pacientes con hipertensión arterial (HTA); se requiere de un método de detección económico y fiable. Objetivo: establecer la utilidad de los criterios electrocardiográficos de voltaje para el diagnóstico de HVI en pacientes con HTA y análisis de los criterios una vez estratificada la HVI. Se realiza un estudio prospectivo de 255 pacientes consecutivos con HTA (161 mujeres, 94 hombres, edad media 59,6 ñ 14 años) con ECG basal y ecocardiograma M y 2-D, en forma independiente y ciega. Se estudia la sensibilidad (S), especificidad (E) y exactitud (EX) diagnóstica de 12 criterios electrocardiográficos de HVI, definida por grosor parietal y masa ventricular con el ecocardiograma. La sensibilidad de todos los criterios es baja (0.05-0.20), con especificidad más elevada (0.87-1), con exactitud varía entre 0.31-0.47. Al estratificar la HVI en leve, moderada y severa, la sensibilidad y especificidad de los criterios electrocardiográficos no cambian, incrementándose la exactitud. Sugerimos un nuevo índice: (RV6-RV5)2+(SV3-SV1)2 mayor 10 mm en 125/165 con HVI y 56/90 sin HVI (S = 0.76, E= 0.62 y EX = 0.38). Conclusiones: los criterios electrocardiográficos de voltaje para diagnóstico de HVI en pacientes con HTA tiene baja sensibilidad con alta especificidad. La exactitud es mayor cuanto mayor es el grado de HVI, sin modificar la sensibilidad